RxDoctor Payments Data

David Saperstein

Neurology · Scottsdale, AZNPI 1871585711

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (60.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Grifols USA, LLC at 52.8% of the total. Reporting peaked in 2022 at $27,784 and has fallen 97.6% since, to $669 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$135,374in general payments, 2019–2025

Across 507 payments — averaging $267.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$71K
  • CSL Behring$12K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • UCB, Inc.$10K
  • Alnylam Pharmaceuticals Inc.$9K
  • Pfizer$7K
  • plus $17K from 39 others
$153,455in research payments, 2019–2025

Across 9 payments — averaging $17,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$153K

What the payments were for

  • Consulting fees$81,20060%
  • Speaking & faculty fees$35,82326%
  • Travel & lodging$7,0145%
  • Food & beverage$11,1668%
  • Education$1100%
  • Other$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,374 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5086$749,737
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5084$621,814
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$371,818
Gamunex-CImmune Globul G/Gly/Iga Avg 4651$347,138
GammakedImmune Globul G/Gly/Iga Avg 4615$171,442
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$76,470
Cromolyn Sodium25$19,575
Droxidopa12$2,001
Gabapentin44$1,709
Pyridostigmine Bromide20$1,188
Mycophenolate Mofetil16$1,064
Promethazine Hcl25$1,064
Guanfacine Hcl12$772
Diphenhydramine Hcl55$757
Sodium Chloride0.9 % Sodium Chloride70$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen, Hizentra$11,574$826,20699 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$10,162$371,81814 claims
Grifols USA, LLCGamunex-C$71,433$347,13851 claims
Kedrion Biopharma, Inc.Gammaked$38$171,44215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.

Other neurology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →